Scarica l'app Stockscreener
12.02
0.66%
-0.08
Dopo l'orario di chiusura:
11.80
-0.22
-1.83%
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4%Time to Buy? - MarketBeat
Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech Gem With An 86% Upside Potential - DirectorsTalk Interviews
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha
Oric Pharmaceuticals stock trades down to 10.69 as oricpharma promotes BTIG conference meeting - Traders Union
Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times
ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire
Oric Pharmaceuticals (ORIC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm
ORIC Launches Phase 3 Himalayas-1 Trial - t.co
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - Sahm
Oric Pharmaceuticals (ORIC) Launches Phase 3 Trial for Prostate Cancer Treatment - GuruFocus
ORIC Pharmaceuticals initiates phase 3 prostate cancer trial - Investing.com
ORIC Pharmaceuticals initiates phase 3 prostate cancer trial By Investing.com - Investing.com India
Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial - Stock Titan
Y Intercept Hong Kong Ltd Sells 229,431 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals director Heyman sells $3,600 in stock - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa
Oric Pharmaceuticals director Heyman sells $3,600 in stock By Investing.com - Investing.com India
Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan - Stock Titan
Price to sales forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - Ad Hoc News
Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView
Form 144 Oric Pharmaceuticals For: 6 July By Investing.com - Investing.com Nigeria
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals Slips 2.49% as Stock Tests Key Support LevelsBreakout Stock Alerts - DonanımHaber
Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan
ORIC Pharmaceuticals grants stock options and r... - Pluang
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):